Katrina J. Church - Mar 14, 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Role: SVP & Chief Compliance Officer
Signature: /s/Anthony D'Adamio, Attorney-in-Fact
Stock symbol: BVS
Transactions as of: Mar 14, 2022
Transactions value $: $0
Form type: 4
Date filed: 4/12/2023, 08:48 PM
Next filing: Jun 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BVS	Class A Common Stock						10.4K	Mar 14, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BVS	Stock Option (Right to Buy)	Award	$0	+37.4K		$0.00	37.4K	Mar 14, 2022	Class A Common Stock	37.4K	$12.66	Direct	F1
transaction	BVS	Restricted Stock Units	Award	$0	+17.2K		$0.00	17.2K	Apr 10, 2023	Class A Common Stock	17.2K		Direct	F2, F3
transaction	BVS	Stock Option (Right to Buy)	Award	$0	+44.8K		$0.00	44.8K	Apr 10, 2023	Class A Common Stock	44.8K	$1.16	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options shall vest in four equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
F2	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F3	The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date.